Here this group designs a hybrid lipoplex for co-delivering p53 plasmid along with MDM2 inhibitor sp141 to hepatocellular carcinoma and lung carcinoma for synergistic anti-tumor treatment. This evidence concerns the gene TP53 and lung carcinoma.